Adaptive Biotech (NASDAQ: ADPT) COO sells 57,180 shares in 10b5-1 plan

robot
Abstract generation in progress

Julie Rubinstein, President and COO of Adaptive Biotechnologies (ADPT), sold 57,180 shares of common stock in open-market transactions in late March. These sales, conducted under a pre-arranged Rule 10b5-1 trading plan adopted on November 18, 2025, followed the exercise of stock options for 44,166 shares. After these transactions, Rubinstein directly holds 455,878 shares of the company’s common stock.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin